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Abstract
Cytomegalovirus is associated with hypercoagulability, and is
reported to increase the risk of venous thrombosis in human
immunodeficiency virus (HIV)-infected patients. Progression to
AIDS, however, is also associated with hypercoagulability and
venous thrombosis, and may result in more comorbidities, such
as reactivation of cytomegalovirus. It is therefore unknown
whether active cytomegalovirus in HIV infection results in a
procoagulant state or whether hypercoagulability is the result of
HIV infection itself. In this cross-sectional study of 104 consecu-
tive HIV-infected patients, active cytomegalovirus infection was
associated with hypercoagulability independently of stage of HIV
disease. This finding may deserve attention in preventative rec-
ommendations for use of thromboprophylaxis in HIV-infected
patients.
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Human immunodeficiency virus (HIV)-infected patients are
at increased risk of arterial and venous thrombosis [1].
Progression of HIV infection to AIDS probably contributes
to this increased risk by inducing a procoagulant state [2–4].
In a large retrospective cohort study, cytomegalovirus
infection increased the risk of venous thrombosis 1.9-fold
(95% CI 1.2–2.9) in HIV-infected patients [5]. As active cyto-
megalovirus infection is common in HIV-infected patients [6],
this may be important for preventative issues in these
patients, e.g. the use of thromboprophylaxis in high-risk situ-
ations. However, as active cytomegalovirus infection may
more often be found in patients with progressive HIV infec-
tion, the finding that cytomegalovirus infection increases
venous thrombotic risk may be confounded by stage of HIV
disease. In this study, our aim was to determine whether
procoagulant abnormalities were associated with active cyto-
megalovirus infection after adjustment for stage of HIV dis-
ease. Between May 2006 and December 2006, 109
consecutive patients with HIV infection treated at the outpa-
tient clinic of our university hospital were asked to partici-
pate in our study, as previously published [4]. For five
individuals, data on cytomegalovirus serology were missing.
Therefore, 104 HIV-infected patients were included in the
present study. Detailed information on date of HIV diagnosis,
stage of HIV disease, HIV treatment, previous episodes of
venous and arterial thrombosis, exposure to risk factors for
thrombosis and anticoagulant treatment was retrospectively
collected by a physician (WML) at the outpatient clinic by
using a standardized questionnaire and reviewing medical
records. Clinical data were collected prior to laboratory
testing to avoid bias in assessing clinical outcome events.
Patients were tested on the following coagulation factors:
factor VIII (elevated >150 IU/dL), fibrinogen (elevated >3.5 g/
L), antithrombin (deficient <65 IU/dL), protein C antigen
(deficient <65 IU/dL), total protein S antigen (deficient
<65 IU/dL), and free protein S antigen (deficient <65 IU/dL).
Cytomegalovirus IgG antibodies were determined by enzyme
immunoassay as previously described [7]. Patients with anti-
cytomegalovirus antibody levels above the 75th percentile
(>209 IU/mL) were defined as patients who had active cyto-
megalovirus infection. This cut-off level corresponds well
with the definition of active cytomegalovirus infection in
more generalized populations [8]. Lymphocyte subset CD4
count, which corresponds to stage of HIV disease, was analy-
sed within 24 h of collection, using standard flow cytometry
techniques.
Continuous variables are expressed as median values and
ranges, because factor VIII, free protein S and fibrinogen
were not normally distributed. For the other anti-coagulant
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factors (antithrombin, protein C, and protein S), the median
did not differ from the mean value. Categorical data are
expressed as counts and percentages. Differences between
patients with active cytomegalovirus infection and patients
with non-active cytomegalovirus infection were evaluated by
the Mann–Whitney U-test and by the Pearson chi-square test
for categorical data. Mean differences between coagulation
factors were calculated with a linear regression model, and
were adjusted for stage of HIV disease. The p-value for trend
was calculated with ANOVA. A two-tailed p-value of <0.05
indicated statistical significance. Statistical analyses were per-
formed with SPSS for Windows, version 16.0.
Of 26 HIV-infected patients with active cytomegalovirus
infection, 73% were men and were enrolled at a median age
of 48 years (range, 31–73 years). For 78 patients without
active cytomegalovirus infection, these values were 64% and
40 years (range, 19–76 years). The median CD4 count in
patients with active cytomegalovirus infection was 305/lL
(range, 80–650/lL), as compared with 450/lL (range,
30–1220/lL) in patients with non-active cytomegalovirus
infection (p <0.001). In patients with active cytomegalovirus
infection, median CD4 counts were 554/lL (range, 510–645/
lL), 360/lL (range, 220–500/lL) and 80/lL (range, 80–200/
lL), respectively, in patients with asymptomatic HIV disease,
symptomatic HIV disease, and AIDS, respectively [4]. In
patients with non-active cytomegalovirus infection, median
CD4 counts were 640/lL (range, 510–1220/lL), 340/lL
(range, 250–430/lL) and 90/lL (range, 30–180/lL), respec-
tively. An increase in levels of IgG antibody against cytomega-
lovirus was associated with significant increases in factor VIII,
fibrinogen, and total protein S (p-values for trend, £0.001,
0.036, and 0.007, respectively). Antithrombin and protein C
remained stable with increasing levels of IgG against cyto-
megalovirus, as did free protein S. However, free protein S
showed median levels that were considered to be deficient
in all groups (Table 1). Large increases in coagulation factor
levels were shown at an IgG antibody level above the 75th
percentile, which corresponds with thecut-off value for
active cytomegalovirus infection that we used and with
experimental studies suggesting that inflammation and coagu-
lation share common pathways [5]. It also corresponds well
with the findings of another study showing that active cyto-
megalovirus infection is associated with enhanced factor VIII
synthesis or secretion [8]. In patients with active vs. non-
active cytomegalovirus infection, 19 (73%) vs. 38 (49%)
patients had elevated factor VIII levels (p 0.03), 12 (46%) vs.
18 (23%) had elevated fibrinogen levels (p 0.02), two (2%)
vs. nine (12%) had protein C deficiency (p 0.72), and 19
(76%) vs. 51 (65%) had free protein S deficiency (p 0.32).
Deficiency of antithrombin or protein S was only recorded
in one case. All patients with active cytomegalovirus infection
had at least one thrombophilic abnormality, vs. 78% of
patients with non-active cytomegalovirus infection (p 0.009).
In Table 2, factor VIII, fibrinogen and total protein S levels
can be seen to be significantly higher in patients with active
cytomegalovirus infection. A similar tendency was shown for
TABLE 1. Median levels of coagulation factors related to cytomegalovirus IgG titre
IgG n
Factor VIII
(IU/dL) (range)
Fibrinogen
(g/L) (range)
Antithrombin
(IU/dL) (range)
Protein C
(IU/dL) (range)
Total protein S
(IU/dL) (range)
Free protein S
(IU/dL) (range)
£25th percentile (£40 IU/mL) 26 140 (59–241) 2.9 (1.8–4.4) 105 (81–131) 101 (64–136) 97 (71–114) 56 (20–135)
25th–50th percentile (41–97 IU/mL) 26 151 (94–222) 2.8 (1.8–4.7) 108 (63–137) 98 (39–174) 98 (65–133) 58 (30–123)
50th–75th percentile (98–208 IU/mL) 26 148 (87–331) 2.9 (1.8–5.6) 111 (90–144) 90 (64–147) 94 (70–142) 51 (23–98)
75th–95th percentile (209–713 IU/mL) 21 180 (107–283) 3.5 (1.7–5.8) 118 (81–140) 104 (62–145) 100 (78–144) 53 (28–138)
>95th percentile (>713 IU/mL) 5 289 (148–342) 3.9 (2.8–5.2) 115 (82–173) 121 (46–144) 120 (110–152) 58 (53–63)
p-value for trend <0.001 0.036 0.069 0.67 0.007 0.54
TABLE 2. Thrombophilic abnormalities related to cytomegalovirus status
Cytomegalovirus infection
Mean difference
(95% CI) p
Mean difference
(95% CI)a pa
Active
(IgG >209 IU/mL)
n = 26
Non-active
(IgG <209 IU/mL)
n = 78
Factor VIII (IU/dL), median (range) 202 (107–342) 147 (59–331) 46 (22–69) <0.001 33 (10–57) 0.006
Fibrinogen (g/L), median (range) 3.5 (1.7–5.8) 2.8 (1.8–5.6) 1 (0.2–1.0) 0.004 1 (0.1–0.9) 0.015
Antithrombin (IU/dL), median (range) 118 (81–173) 106 (63–144) 8 (1–15) 0.052 8 (0–16) 0.050
Protein C (IU/dL), median (range) 105 (46–145) 95 (39–174) 7 ()5 to 18) 0.241 7 ()5 to 19) 0.227
Total protein S (IU/dL), median (range) 107 (78–152) 97 (65–142) 14 (5–22) 0.002 15 (6–24) 0.001
Free protein S (IU/dL), median (range) 53 (28–138) 55 (20–135) 0 ()11 to 10) 0.951 5 ()6 to 16) 0.349
aAdjusted for stage of human immunodeficiency virus disease.
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antithrombin levels (p 0.052). Although adjustment for stage
of HIV disease narrowed the mean difference in factor VIII
between the two groups, all of the aforementioned differ-
ences remained statistically significant after adjustment.
In this study, active cytomegalovirus infection was associ-
ated with a procoagulant state. Although active cytomegalo-
virus infection was more commonly found in patients with
AIDS than in patients with symptomatic HIV disease, adjust-
ment for stage of HIV disease did not result in similar levels
of coagulation factors in patients with active and those with
non-active cytomegalovirus infection. Interestingly, we also
observed higher levels of anticoagulant factors (higher anti-
thrombin and total protein S levels) and higher procoagulant
factor levels (higher factor VIII and fibrinogen levels) at the
time of active cytomegalovirus infection. This result is in line
with other studies that suggest a tight interplay between
coagulation and inflammation at the time of acute infection
[9]. It is also in line with results from the ARIC study, where
apparently healthy individuals with cytomegalovirus infection
had higher factor VIII, fibrinogen and antithrombin levels than
cytomegalovirus-naı¨ve individuals [10,11]. Because elevated
levels of factor VIII and fibrinogen are well-known risk factors
for thrombosis in the general population [12–14], and were
more commonly observed in patients with active cytomegalo-
virus infection, and because higher levels of antithrombin and
total protein S are not associated with a decreased risk of
thrombosis in general populations, the results of this study
suggest that the balance in the relationship has been shifted
to a procoagulant state, as also suggested by others [10].
A shortcoming of this study might be that we did not
measure cytomegalovirus viraemia by PCR or antigenaemia.
A positive viral load may be considered as a reference stan-
dard for the diagnosis of active cytomegalovirus infection.
However, this assay has positive value only at the start of
infection, whereas cytomegalovirus IgG antibodies seem to
be stable for at least 18 months [15]. Hence, high cytomega-
lovirus IgG antibody levels are probably related to a (previ-
ously) reactivated or periodically activated virus infection in
our patients.
In conclusion, active cytomegalovirus infection was associ-
ated with a procoagulant state independently of stage of HIV
disease. This finding may deserve attention, in for example,
preventative recommendations for the use of thrombopro-
phylaxis when HIV-infected patients are exposed to situa-
tions of high venous thrombotic risk.
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